Literature DB >> 20865478

Porphyrias at a glance: diagnosis and treatment.

Maria Domenica Cappellini1, Valentina Brancaleoni, Giovanna Graziadei, Dario Tavazzi, Elena Di Pierro.   

Abstract

Porphyrias are a group of eight rare inherited metabolic disorders of heme biosynthesis pathway. Porphyrias are still underdiagnosed, although examinations of urine and plasma are first-line tests for detecting excess of porphyrins or heme precursors in suspected patients. Diagnosis, particularly for the acute forms, is essential to avoid precipitating factors and the use of triggering drugs. Mutation screening of family members is recommended to identify presymptomatic carriers and to prevent acute attacks. The therapeutic approach should be appropriate regarding specific forms of porphyria and treatment should be started promptly.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20865478     DOI: 10.1007/s11739-010-0449-7

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  75 in total

1.  C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload.

Authors:  Sharon D Whatley; Sarah Ducamp; Laurent Gouya; Bernard Grandchamp; Carole Beaumont; Michael N Badminton; George H Elder; S Alexander Holme; Alexander V Anstey; Michelle Parker; Anne V Corrigall; Peter N Meissner; Richard J Hift; Joanne T Marsden; Yun Ma; Giorgina Mieli-Vergani; Jean-Charles Deybach; Hervé Puy
Journal:  Am J Hum Genet       Date:  2008-09-04       Impact factor: 11.025

2.  Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria.

Authors:  H Puy; J C Deybach; J Lamoril; A M Robreau; V Da Silva; L Gouya; B Grandchamp; Y Nordmann
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

3.  Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda.

Authors:  Z J Bulaj; J D Phillips; R S Ajioka; M R Franklin; L M Griffen; D J Guinee; C Q Edwards; J P Kushner
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

4.  Successful treatment of haemodialysis-related porphyria cutanea tarda with erythropoietin.

Authors:  R Peces; R Enríquez de Salamanca; A Fontanellas; A Sánchez; M de la Torre; G Caparros; I Ferreras; J Nieto
Journal:  Nephrol Dial Transplant       Date:  1994       Impact factor: 5.992

5.  Urine and faecal porphyrin profiles by reversed-phase high-performance liquid chromatography in the porphyrias.

Authors:  C K Lim; T J Peters
Journal:  Clin Chim Acta       Date:  1984-05-16       Impact factor: 3.786

6.  Crystal structure of ferrochelatase: the terminal enzyme in heme biosynthesis.

Authors:  S Al-Karadaghi; M Hansson; S Nikonov; B Jönsson; L Hederstedt
Journal:  Structure       Date:  1997-11-15       Impact factor: 5.006

7.  Inheritance in erythropoietic protoporphyria: a common wild-type ferrochelatase allelic variant with low expression accounts for clinical manifestation.

Authors:  L Gouya; H Puy; J Lamoril; V Da Silva; B Grandchamp; Y Nordmann; J C Deybach
Journal:  Blood       Date:  1999-03-15       Impact factor: 22.113

8.  Plasma fluorescence scanning and fecal porphyrin analysis for the diagnosis of variegate porphyria: precise determination of sensitivity and specificity with detection of protoporphyrinogen oxidase mutations as a reference standard.

Authors:  Richard J Hift; Brandon P Davidson; Cornelis van der Hooft; Doreen M Meissner; Peter N Meissner
Journal:  Clin Chem       Date:  2004-02-19       Impact factor: 8.327

9.  Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study.

Authors:  Ingemar Bylesjö; Agneta Wikberg; Christer Andersson
Journal:  Scand J Clin Lab Invest       Date:  2009       Impact factor: 1.713

10.  Hypertension and renal disease in patients with acute intermittent porphyria.

Authors:  C Andersson; F Lithner
Journal:  J Intern Med       Date:  1994-08       Impact factor: 8.989

View more
  5 in total

1.  Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: A qualitative study.

Authors:  Hetanshi Naik; Mikayla Stoecker; Saskia C Sanderson; Manisha Balwani; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2016-08-24       Impact factor: 4.797

2.  An unusual diagnosis in a 31-year-old man with abdominal pain and hyponatremia.

Authors:  Federica Depetri; Massimo Cugno; Giovanna Graziadei; Elena Di Pierro; Francesca Granata; Flora Peyvandi; Maria Domenica Cappellini
Journal:  Intern Emerg Med       Date:  2018-03-17       Impact factor: 3.397

3.  Heme acts through the Bach1b/Nrf2a-MafK pathway to regulate exocrine peptidase precursor genes in porphyric zebrafish.

Authors:  Shuqing Zhang; Minrui Xu; Jian Huang; Lili Tang; Yanqing Zhang; Jingyao Wu; Shuo Lin; Han Wang
Journal:  Dis Model Mech       Date:  2014-03-20       Impact factor: 5.758

4.  Heme biosynthesis depends on previously unrecognized acquisition of iron-sulfur cofactors in human amino-levulinic acid dehydratase.

Authors:  Gang Liu; Debangsu Sil; Nunziata Maio; Wing-Hang Tong; J Martin Bollinger; Carsten Krebs; Tracey Ann Rouault
Journal:  Nat Commun       Date:  2020-12-09       Impact factor: 14.919

5.  The potential role of cell penetrating peptides in the intracellular delivery of proteins for therapy of erythroid related disorders.

Authors:  Lefkothea C Papadopoulou; Asterios S Tsiftsoglou
Journal:  Pharmaceuticals (Basel)       Date:  2013-01-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.